首页 | 本学科首页   官方微博 | 高级检索  
     

荧光原位杂交检测乳腺癌HER2基因状态
引用本文:Zeng X,Zhao DC,Zhou WX,Wu SF,Liang ZY,Liu TH. 荧光原位杂交检测乳腺癌HER2基因状态[J]. 中华病理学杂志, 2005, 34(11): 701-705
作者姓名:Zeng X  Zhao DC  Zhou WX  Wu SF  Liang ZY  Liu TH
作者单位:100730,中国医学科学院,中国协和医科大学,北京协和医院病理科
摘    要:目的 探讨荧光原位杂交(FISH),与免疫组织化学(IHC)染色(3+)和(2+)检测HER2基因状态的结果的一致性、导致两者差异的可能原因及FISH检测HER2基因状态的必要性和可行性。方法 采用PathVysion^TM探针试剂盒,以FISH方法,对28例IHC EnVision法染色分别为(3+)、(2+)、(1+)和阴性(-)的乳腺癌石蜡切片标本进行HER2基因状态的检测。结果 HER2表达(3+)的12例标本中,10例HER2基L大1扩增,其中2例为17号染色体多体,另2例无扩增的病例均为多体;IHC为(2+)的10例标本中,7例为HER2基因扩增,其中1例为多体,另3例无扩增病例中2例为多体;IHC为(1+)的3例标本均无HER2基因扩增,其中1例为多体;IHC(-)的3例标本均无基因扩增,其中1例为多体。结论 IHC是初步筛查HER2状态的首选方法;因IHC(2+)与FISH检测结果差异较大,所以这类患者应做FISH确诊;IHC(3+)存在假阳性,主要原因可能是由于17号染色体非整倍体,必要时这类患者也应做FISH。

关 键 词:乳腺肿瘤 免疫组织化学 荧光原位杂交 基因  c-erbB-2(HER2)
收稿时间:2005-06-08
修稿时间:2005-06-08

Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization
Zeng Xuan,Zhao Da-Chun,Zhou Wei-Xun,Wu Sha-Fei,Liang Zhi-Yong,Liu Tong-Hua. Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization[J]. Chinese Journal of Pathology, 2005, 34(11): 701-705
Authors:Zeng Xuan  Zhao Da-Chun  Zhou Wei-Xun  Wu Sha-Fei  Liang Zhi-Yong  Liu Tong-Hua
Affiliation:Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China
Abstract:Objective To deduce the protocol, scoring criteria and interpretive guidelines for assessment of HER2 gene expression status by fluorescence in-situ hybridization (FISH) and to compare the results with those obtained by immunohistochemistry. Methods The HercepTest TM kit from Dako Cytomation was employed for immunohistochemistry. FISH for HER2 gene expression status was performed using PathVysion TM DNA probe kit on the archival paraffin-embedded sections of breast cancer tissues from 28 Chinese female patients with immunohistochemical staining scores of (3+),(2+),(1+) and 0. Results Ten of the 12 patients with score (3+) by immunohistochemistry were positive for HER2 by FISH, with 2 cases being polysomy. Two other cases with FISH-negative were also shown to be polysomy. Seven of the 10 patients with score (2+) by immunohistochemistry showed HER2 gene amplification, with 1 case being polysomy. Two of the remaining 3 cases, which were FISH-negative, were shown to be polysomy. All the patients with scores (1+,number=3) or 0 (number=3) by immunohistochemistry failed to show amplification. One case of polysomy was noted in either group. Conclusions Immunohistochemistry is useful as an initial screening tool for HER2 expression status. Because of the obvious discrepancies between protein expression and gene amplification, patients with score (2+) by immunohistochemistry should undergo FISH testing as well. FISH is also required in selected examples with score (3+) immunohistochemical results, especially in those with false-positive immunohistochemistry due to chromosome 17 aneuploidy.
Keywords:Breast neoplasms  Immunohistochemistry  In situ hybridization   fluorescence  Gene   c-erbB-2 (HER2)  
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号